» Articles » PMID: 16637057

Increased Expression of Nuclear Factor E2 P45-related Factor 2 (NRF2) in Head and Neck Squamous Cell Carcinomas

Overview
Journal Head Neck
Date 2006 Apr 26
PMID 16637057
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Head and neck squamous cell carcinoma (HNSCC) continues to cause significant morbidity and mortality. Overexpression of specific phase II gene products may represent an important biomarker. One regulator of phase II gene expression is the transcription factor nuclear factor E2 p45-related factor 2 (Nrf2). Nrf2 expression was evaluated in HNSCC, to determine whether it might serve as a biomarker for early detection of disease.

Methods: A tissue microarray was constructed of 141 HNSCC biopsy cores from 47 HNSCCs. In addition, histologically normal squamous mucosa was obtained from 7 patients. Protein expression was evaluated by immunohistochemistry.

Results: Nrf2 expression was increased in 91.5% of tumors. Expression of thioredoxin, a Nrf2-reguated gene product, was elevated in 75% of tumors. Keap1, which regulates the rate of Nrf2 ubiquitination and degradation, was relatively overexpressed in HNSCC compared with normal mucosa.

Conclusions: Nrf2 expression may be a possible HNSCC candidate biomarker.

Citing Articles

Dual role of Nrf2 signaling in hepatocellular carcinoma: promoting development, immune evasion, and therapeutic challenges.

Gan L, Wang W, Jiang J, Tian K, Liu W, Cao Z Front Immunol. 2024; 15:1429836.

PMID: 39286246 PMC: 11402828. DOI: 10.3389/fimmu.2024.1429836.


Co-targeting NRF2 potentially enhances the in vitro anticancer effects of paclitaxel in gastric cancer cells.

Hasani S, Khalaj-Kondori M, Safaei S, Amini M, Riazi-Tabrizi N, Maghsoudi M Discov Oncol. 2024; 15(1):424.

PMID: 39256224 PMC: 11387580. DOI: 10.1007/s12672-024-01312-6.


CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC.

Rahman M, Hossain M, Islam S, Ahmed R, Majumder M, Dey S BMC Mol Cell Biol. 2024; 25(1):4.

PMID: 38336617 PMC: 10858504. DOI: 10.1186/s12860-024-00500-0.


Nrf2, A Target for Precision Oncology in Cancer Prognosis and Treatment.

Ngo H, Le H, Surh Y J Cancer Prev. 2024; 28(4):131-142.

PMID: 38205365 PMC: 10774478. DOI: 10.15430/JCP.2023.28.4.131.


Targeting NEDDylation is a Novel Strategy to Attenuate Cisplatin-induced Nephrotoxicity.

Jones T, Espitia C, Chipollini J, Lee B, Wertheim J, Carew J Cancer Res Commun. 2023; 3(2):245-257.

PMID: 36860653 PMC: 9973416. DOI: 10.1158/2767-9764.CRC-22-0340.